LoadingLoadingLoadingThe quick read
Latest quote·Oct 14
Net selling: insiders sold $6.3M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsNet selling: insiders sold $6.3M and bought $0 of CI stock on the open market in the 90 days to Oct 16, 2026, according to SEC Form 4 filings. $6.3M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Jones, Nicole S (See Remarks), who sold $6.1M. The latest filing was on Sep 8, 2026.
None. No member of Congress disclosed a CI trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
This summary uses filings available on Oct 16, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
8 funds hold a position and insiders have been net selling.
Buys/Adds (3)
Two Sigma
$328.8M
added
Squarepoint
$101.2M
added
Millennium
$92.1M
added
Buys (1)
Sells (2)
No tracked top-trader positions in CI right now.
Live Hyperliquid positioning - not every stock is covered
Last report
Jul 30, 2026
Financial period
Q2
Adjusted EPS
$7.60 expected
Revenue
No comparable estimate
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 30, 2026 | $7.78 / $7.60Yahoo Finance | +2.37% beat | $71.67B / Unavailable | Unavailable |
| Mar 31, 2026 | Apr 30, 2026 | $7.79 / $7.61Yahoo Finance | +2.41% beat | Unavailable | Unavailable |
| Dec 31, 2025 | Feb 5, 2026 | $8.08 / $7.88Yahoo Finance | +2.50% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Oct 30, 2025 | $7.83 / $7.64Yahoo Finance | +2.47% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Jul 31, 2025 | $7.20 / $7.15Alpha Vantage | +0.70% in line | Unavailable | Unavailable |
| Mar 31, 2025 | May 2, 2025 | $6.74 / $6.35Alpha Vantage | +6.14% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Jan 30, 2025 | $6.64 / $7.82Alpha Vantage | -15.09% miss | Unavailable | Unavailable |
| Sep 30, 2024 | Oct 31, 2024 | $7.51 / $7.25Alpha Vantage | +3.59% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Estimates as of Oct 15, 2026
EPS expected
$7.42 to $7.71
Revenue expected
13 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $69.75B | $72.47B | $68.49B | $71.67B |
| Cost of what it sold | $63.81B | $66.92B | $62.02B | $56.70B |
| Gross profit | $5.94B | $5.55B | $6.47B | $14.96B |
| What it spent | ||||
| Sales and admin | $3.36B | $3.41B | $3.72B | $3.47B |
| Other operating costs | — | — | $390.0M | $8.82B |
| Total operating expenses | $3.36B | $3.41B | $4.11B | $12.29B |
| What was left | ||||
| Operating profit | $2.58B | $2.15B | $2.36B | $2.68B |
| Interest on debt | $347.0M | $335.0M | $357.0M | $356.0M |
| Profit before tax | $2.29B | $1.63B | $2.27B | $2.26B |
| Tax | $322.0M | $395.0M | $409.0M | $382.0M |
| Net profit | $1.87B | $1.23B | $1.65B | $1.66B |
| EBITDA | $3.34B | $2.69B | $3.28B | $3.27B |
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
CVS Health stock trades at EUR 79.72 with a 23.36 price-to-earnings ratio
Leans bullishOct 13Mizuho Adjusts Price Target on Intuitive Surgical to $415 From $400
NeutralOct 13Cigna reaffirmed 2026 outlook while Cigna Group stock trades at EUR 254.15
Leans bullishOct 13Certain Common Stock of Zentalis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-OCT-2026.
NeutralOct 13Progyny Inc. Research & Ratings | PGNY
NeutralOct 12Cigna Group stock at USD 282.52, P/ E 11.7
Leans bullishOct 12Elevance Health stock at EUR 376.05 with P/ E 18.6
NeutralOct 12Evercore ISI Adjusts Price Target on Apollo Global Management to $138 From $146
NeutralOct 12